BioLargo subsidiary Clyra Medical names new CRO and business development head

BioLargo subsidiary Clyra Medical names new CRO and business development head

Proactive Investors

Published

BioLargo Inc (OTCQB:BLGO) subsidiary Clyra Medical Technologies Inc has recruited two experienced business executives as it launches the Clyraguard personal protection spray to help protect non-critical personal protective equipment from the SARS-CoV-2 virus which causes the COVID-19 disease.  Shawn Dougherty will serve as chief revenue officer with John Sirpilla taking over as chief business development officer, the company said in a statement Tuesday. Dougherty is an entrepreneur with substantial experience growing sales and revenues for new and innovative products. Prior to joining Clyra, she co-founded mophie, the number one selling battery case manufacturer for mobile devices in North America. As COO and founder, she helped mophie create the first juice pack battery case for the iPhone in North America and built an exclusive partnership with Apple Inc (NASDAQ:AAPL).  READ: BioLargo says subsidiary's Clyraguard protective spray inactivates SARS-CoV-2 virus in lab tests Sirpilla is the former president of Camping World Accessory Stores, a 140-store nationwide retail chain serving the RV industry and was promoted in 2012 to chief business development officer for the parent company, Camping World and Good Sam with annual sales of nearly $4 billion.  He is currently the CEO and founder of Encourage LLC, a family office focused on driving change in healthy living, leadership, and child adoption. Clyraguard is a personal protective spray designed to help frontline healthcare workers prevent cross-contamination of their personal protective equipment from SARS-CoV-2, the virus that causes COVID-19. The product is colorless and odorless and has been found to be non-toxic, non-irritating, non-sensitizing and non-staining. Testing at the Galveston National Laboratory at the University of Texas Medical Branch found the spray completely inactivates the SARS-CoV-2 virus. Contact the author: patrick@proactiveinvestors.com Follow him on Twitter @PatrickMGraham

Full Article